First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3: Final phase 1 data and preliminary activity in HER2+metastatic breast cancer (MBC).

被引：40

作者：

Alsina, Maria

Boni, Valentina

Schellens, Jan H. M.

Moreno, Victor

Bol, Kees

Westendorp, Martine

Sirulnik, L. Andres

Tabernero, Josep

Calvo, Emiliano

机构：

[1] Vall Hebron Univ Hosp, Barcelona, Spain

[2] START Madrid CIOCC, Hosp HM Univ Sanchinarro, Madrid, Spain

[3] Netherlands Canc Inst, Amsterdam, Netherlands

[4] Start Madrid FJD, Hosp Fdn, Madrid, Spain

[5] Merus NV, Utrecht, Netherlands

[6] Vall Hebron Univ Hosp, Inst Oncol VHIO, Barcelona, Spain

[7] START Madrid, Centro Integral Oncol Clara Campal, Madrid, Spain

来源：

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.2522

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2522

引用

页数：6